Volver

Merck & Company Inc

Ticker: MRK ISIN: US58933Y1055
Añadir al portafolio Análisis de cartera en 2min
Stock Large-cap Dividend payer Trading above 200-day average Near 52-week high
Capitalización
210,34 MM $
P/E
12,98
Forward P/E
9,43
Profit margin
25,79%
Revenue growth QoQ
-1,90%
Div. yield
3,82%
Beta
0,39
150,66 $ -1,24%
Precio a fecha de 2026-08-24 · NYSE

Rendimiento por período

Rendimientos acumulados
1 Month +15,22%
6 Months +23,35%
1 Year +82,51%
5 Years +18,14% p.a.+129,97%
10 Years +13,05% p.a.+240,54%
Since inception +7,51% p.a.+510,35%
Rendimientos por año
YTD +45,23%
2025 +9,79%
2024 -6,26%
2023 +1,01%
2022 +49,42%
2021 +1,75%

Key stats

Market cap
210,34 MM
P/E
12,98
Dividend yield
3,82%
Beta
0,39
52-week range
72.58 - 116.37
50-day MA
81,09
200-day MA
88,77
Section 1

Business overview

Company profile data from fundamentals.

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The company offers human health pharmaceutical for various areas, including oncology, vaccines, hospital acute care, cardiovascular, virology, neuroscience, and diabetes under the Keytruda, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. It also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions for animal identification, monitoring and traceability; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. The company has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. It has a collaboration agreement with Antengene Corporation Limited to evaluate the combination of ATG-022, a CLDN18.2-targeting antibody-drug conjugate, and ant

Sector Healthcare
Industry Drug Manufacturers - General
Country United States
Exchange NYSE
Section 2

Financial quality

Profitability and balance-sheet quality indicators from reported fundamentals.

Profitability

ROE 35,42%
ROA 13,01%
Profit margin 25,79%
Operating margin 37,47%
PEG ratio 0,83
Revenue/share TTM 25,21
Revenue TTM 63,62 MM
EBITDA 28,33 MM
Gross profit TTM 49,25 MM
Beta 0,39

Valuation

Trailing P/E 12,98
Forward P/E 9,43
P/B 4,29
P/S 3,31
EV/EBITDA 9,47
EV/Revenue 3,73

ESG Scores

Total ESG 28,4
Environment 3,1
Social 15,6
Governance 12,7
Section 3

Earnings

Earnings metrics from company highlights and earnings datasets.

EPS estimate (current year) 8,93
Quarterly earnings growth -17,80%
Revenue TTM 63,62 MM
Reported quarters 124
Section 4

Dividends & corporate actions

Dividend and split fields from fundamentals.

Dividend yield 3,82%
Forward annual div. yield 3,85%
Dividend per share 3,1600
Payout ratio 42,41%
Ex-dividend date 2025-09-15
Next dividend date 2025-10-07
Split factor 1048:1000
Last split date 2021-06-03
Section 5

Ownership / analyst view

Institutional ownership and analyst estimate fields when available.

Analyst

Analyst target price 101,79 $
Analyst rating 4.0385

Ownership & short interest

Shares outstanding 2,50 MM
Shares float 2,49 MM
Institutional ownership 80,43%
Insider ownership 6,70%
Short ratio 1,92
Short % of float 1,15%

Details

Instrument metadata and source update timestamps.

Symbol MRK
Name Merck & Company Inc
Asset type STOCK
Exchange NYSE
Currency USD
ISIN US58933Y1055
Country USA
Code + exchange MRK.NYSE
Last price date 2025-08-15
Fundamentals updated 2025-08-16

La información proporcionada en esta plataforma es solo para fines informativos y no debe considerarse como asesoramiento financiero o de inversión. Insightfolio no ofrece asesoramiento financiero, recomendaciones personalizadas ni orientación sobre la compra, tenencia o venta de activos financieros. Las herramientas y contenidos son únicamente educativos y no están adaptados a las circunstancias, necesidades financieras u objetivos personales.

Insightfolio no asume ninguna responsabilidad por la precisión, integridad o fiabilidad de la información presentada. Es responsabilidad exclusiva de los usuarios verificar la información y tomar decisiones independientes basándose en su propia investigación y consideración. El uso de esta plataforma no reemplaza la consulta con profesionales financieros cualificados.

Invertir implica riesgos. Los usuarios deben ser conscientes de que el valor de las inversiones puede fluctuar y que los rendimientos pasados no son garantía de resultados futuros. Las decisiones de inversión deben basarse en objetivos financieros personales, tolerancia al riesgo y una evaluación independiente de la información relevante.

Insightfolio no respalda ni garantiza la idoneidad de ningún producto financiero, valor o estrategia en particular. Cualquier proyección, pronóstico o escenario hipotético presentado en la plataforma es solo ilustrativo y no constituye una garantía.

Al acceder a los servicios, información o contenido ofrecido por Insightfolio, los usuarios reconocen y aceptan los términos de este aviso legal. Si no estás de acuerdo con estos términos, por favor no uses nuestra plataforma.

Logotipos de instrumentos proporcionados por Elbstream.